Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Department of Anesthesiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Front Immunol. 2020 Oct 21;11:544563. doi: 10.3389/fimmu.2020.544563. eCollection 2020.
Glioblastoma (GBM) is the most malignant form of astrocytoma with short survival and a high recurrence rate and remains a global problem. Currently, surgery, chemotherapy, radiotherapy, and other comprehensive treatments are the main treatment modalities, but patients still have a poor prognosis mainly due to the infiltrative growth of GBM and the protective effect of the blood-brain barrier on tumor cells. Therefore, immunotherapy is expected to be a good option for GBM. In the immune system, different cells play varying roles in the treatment of GBM, so understanding the roles played by various immune cells in treating GBM and considering how to combine these effects to maximize the efficacy of these cells is important for the selection of comprehensive and optimal treatment plans and improving GBM prognosis. Therefore, this study reviews the latest research progress on the role of various types of immune cells in the treatment of GBM.
胶质母细胞瘤（GBM）是最恶性的星形细胞瘤，生存时间短，复发率高，仍然是一个全球性的问题。目前，手术、化疗、放疗等综合治疗是主要的治疗方法，但患者预后仍然较差，主要是由于 GBM 的浸润性生长和血脑屏障对肿瘤细胞的保护作用。因此，免疫疗法有望成为 GBM 的一种较好的选择。在免疫系统中，不同的细胞在治疗 GBM 中发挥着不同的作用，因此了解各种免疫细胞在治疗 GBM 中的作用，并考虑如何结合这些作用以最大限度地发挥这些细胞的疗效，对于选择综合和最佳的治疗方案以及改善 GBM 的预后非常重要。因此，本研究综述了各种类型的免疫细胞在治疗 GBM 中的作用的最新研究进展。
